The Risks and Benefits of Finerenone

Thursday, May 12, 2022

11:00 AM – 12:00 PM

Location: Main Stage - Sapphire IJMN (Level 4)

Speaker(s)

Katherine R. Tuttle, MD, FASN, FACP, FNKF
Professor of Medicine
University of Washington
Spokane, Washington, United States

Disclosure: AstraZeneca (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Bayer (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Boehringer Ingelheim (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Eli Lilly (Self) : Honorarium (Status: Ongoing); Gilead (Self) : Grant/Research Support (Status: Ongoing); Goldfinch Bio (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Grant/Research Support (Status: Ongoing); Travere (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing)

PDF Slides

Learning Objectives:

Identify the prevalence and risks of diabetes and chronic kidney disease (CKD).
Recognize the current standards-of-care for diabetes and CKD to reduce kidney and cardiovascular disease (CVD) risks.
Discuss use of finerenone in the context of personalized approaches to care of persons with diabetes and CKD.

Participants should be aware of the following financial/non-financial relationships:

Katherine R. Tuttle, MD, FASN, FACP, FNKF: AstraZeneca (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Bayer (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Research Grant; Boehringer Ingelheim (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Eli Lilly (Individual(s) Involved: Self): Honorarium; Gilead (Individual(s) Involved: Self): Grant/Research Support; Goldfinch Bio (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Research Grant; Novo Nordisk (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Grant/Research Support; Travere (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Research Grant